Delivery Systems for Acute Migraine Medications

Overview

Journal Can Fam Physician

Specialties General Medicine
Public Health

Date 2001 Mar 3

PMID 11228033

Citations 2

Authors

I Worthington

Affiliations

Soon will be listed here.

Abstract

Objective: To discuss advantages and disadvantages of various routes of administration and delivery systems for acute migraine medications, and to assist family physicians in optimizing treatment for individual patients.

Quality Of Evidence: A MEDLINE search from January 1966 to October 2000 and a Current Contents search for the year 1999 to October 2000 were conducted. Randomized controlled trials were selected, when available. Also included are guidelines (Canadian), non-blinded trials, systematic reviews, and population-based studies.

Main Message: Selecting an appropriate way to deliver medication is important in acute migraine therapy. The parenteral route has advantages, such as rapid onset, greater efficacy, and the possibility of use during nausea and vomiting. Disadvantages include local site discomfort, inconvenience, and patients' dislike of needles. Most patients prefer oral therapy, but gastric stasis and nausea and vomiting during a migraine attack might limit its use. The intranasal route usually provides fairly rapid onset, but side effects, such as disturbances in taste, can occur. The rectal route is another option, but absorption is sometimes erratic, rectal irritation can occur, and few migraine medications are available in rectal formulation.

Conclusion: Selection of appropriate medications and suitable delivery systems for individual patients, based on the characteristics of their attacks (e.g., severity, speed of progression to severe intensity, degree of associated symptoms), ease of administration, and patient preference, will optimize therapy for acute migraine attacks.

Citing Articles

Efficacy and safety of intranasal agents for the acute treatment of migraine: a systematic review and network meta-analysis.

Li G, Duan S, Zhu T, Ren Z, Xia H, Wang Z J Headache Pain. 2023; 24(1):129.

PMID: 37723470 PMC: 10506288. DOI: 10.1186/s10194-023-01662-6.

Delivery of Dihydroergotamine Mesylate to the Upper Nasal Space for the Acute Treatment of Migraine: Technology in Action.

Cooper W, Ray S, Aurora S, Shrewsbury S, Fuller C, Davies G J Aerosol Med Pulm Drug Deliv. 2022; 35(6):321-332.

PMID: 36108289 PMC: 9807280. DOI: 10.1089/jamp.2022.0005.

References

Weisz M, BLUMENTHAL H . Home administration of intramuscular DHE for the treatment of acute migraine headache. Headache. 1994; 34(6):371-3. DOI: 10.1111/j.1526-4610.1994.hed3406371.x. View

Kramer M, Matzura-Wolfe D, Polis A, Getson A, Amaraneni P, Solbach M . A placebo-controlled crossover study of rizatriptan in the treatment of multiple migraine attacks. Rizatriptan Multiple Attack Study Group. Neurology. 1998; 51(3):773-81. DOI: 10.1212/wnl.51.3.773. View

Jones E, Gonzalez E, Boggs J, Grillo J, Elswick Jr R . Safety and efficacy of rectal prochlorperazine for the treatment of migraine in the emergency department. Ann Emerg Med. 1994; 24(2):237-41. DOI: 10.1016/s0196-0644(94)70135-0. View

Adelman J, Mannix L, Von Seggern R . Rizatriptan tablet versus wafer: patient preference. Headache. 2000; 40(5):371-2. DOI: 10.1046/j.1526-4610.2000.00055.x. View

Lavin P . Subacute angle-closure glaucoma as a cause of headache. Headache. 2001; 39(7):520-1. View

Gruffydd-Jones K, Hood C, Price D . A within-patient comparison of subcutaneous and oral sumatriptan in the acute treatment of migraine in general practice. Cephalalgia. 1997; 17(1):31-6. DOI: 10.1046/j.1468-2982.1997.1701031.x. View

Diamond S, Elkind A, Jackson R, Ryan R, DeBussey S, Asgharnejad M . Multiple-attack efficacy and tolerability of sumatriptan nasal spray in the treatment of migraine. Arch Fam Med. 1998; 7(3):234-40. DOI: 10.1001/archfami.7.3.234. View

Ahrens S, Farmer M, Williams D, Willoughby E, Jiang K, Block G . Efficacy and safety of rizatriptan wafer for the acute treatment of migraine. Rizatriptan Wafer Protocol 049 Study Group. Cephalalgia. 1999; 19(5):525-30. DOI: 10.1046/j.1468-2982.1999.019005525.x. View

Cady R, Ryan R, Jhingran P, OQuinn S, Pait D . Sumatriptan injection reduces productivity loss during a migraine attack: results of a double-blind, placebo-controlled trial. Arch Intern Med. 1998; 158(9):1013-8. DOI: 10.1001/archinte.158.9.1013. View

10.

Dodick D, EDMEADS J, Gawel M, Nelson R, Purdy R, Robinson G . Guidelines for the nonpharmacologic management of migraine in clinical practice. Canadian Headache Society. CMAJ. 1998; 159(1):47-54. PMC: 1229482. View

11.

Stewart W, Shechter A, Rasmussen B . Migraine prevalence. A review of population-based studies. Neurology. 1994; 44(6 Suppl 4):S17-23. View

12.

Tfelt-Hansen P . Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: a systematic review based on number needed to treat. Cephalalgia. 1998; 18(8):532-8. DOI: 10.1046/j.1468-2982.1998.1808532.x. View

13.

Becker W, Riess C, Hoag J . Effectiveness of subcutaneous dihydroergotamine by home injection for migraine. Headache. 1996; 36(3):144-8. DOI: 10.1046/j.1526-4610.1996.3603144.x. View

14.

Klapper J, Stanton J . Clinical experience with patient administered subcutaneous dihydroergotamine mesylate in refractory headaches. Headache. 1992; 32(1):21-3. DOI: 10.1111/j.1526-4610.1992.hed3201021.x. View

15.

MacGregor E, WILKINSON M, Bancroft K . Domperidone plus paracetamol in the treatment of migraine. Cephalalgia. 1993; 13(2):124-7. DOI: 10.1046/j.1468-2982.1993.1302124.x. View

16.

Kellstein D, Lipton R, Geetha R, Koronkiewicz K, Evans F, Stewart W . Evaluation of a novel solubilized formulation of ibuprofen in the treatment of migraine headache: a randomized, double-blind, placebo-controlled, dose-ranging study. Cephalalgia. 2000; 20(4):233-43. DOI: 10.1046/j.1468-2982.2000.00055.x. View

17.

Ashford E, Salonen R, Saiers J, Woessner M . Consistency of response to sumatriptan nasal spray across patient subgroups and migraine types. Cephalalgia. 1998; 18(5):273-7. DOI: 10.1046/j.1468-2982.1998.1805273.x. View

18.

Dodick D, EDMEADS J, Gawel M, Nelson R, Purdy R, Robinson G . Guidelines for the diagnosis and management of migraine in clinical practice. Canadian Headache Society. CMAJ. 1997; 156(9):1273-87. PMC: 1227329. View

19.

Dahlof , Solomon . The burden of migraine to the individual sufferer: a review. Eur J Neurol. 1999; 5(6):525-533. DOI: 10.1046/j.1468-1331.1998.560525.x. View

20.

Thomsen L, Dixon R, Lassen L, Gibbens M, Langemark M, Bendtsen L . 311C90 (Zolmitriptan), a novel centrally and peripheral acting oral 5-hydroxytryptamine-1D agonist: a comparison of its absorption during a migraine attack and in a migraine-free period. Cephalalgia. 1996; 16(4):270-5. DOI: 10.1046/j.1468-2982.1996.1604270.x. View